Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Neoadjuvant Docetaxel and Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate

NCT00651326 is registered in ClinicalTrials.gov with NCIC Clinical Trials Group as lead sponsor.

NCT NCT00651326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00651326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Neoadjuvant Docetaxel and Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate
Lead sponsor
NCIC Clinical Trials Group
Phase
Phase 3
Overall status
Terminated
Start date
June 2, 2008
Completion date
January 18, 2011
Enrollment
48 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer